Radiation, Vancomycin, and CAR-T for B-Cell Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional study explores whether a bridging strategy using radiation therapy combined with oral vancomycin is feasible prior to standard anti-CD19 CAR-T treatment in adults with large B-cell non-Hodgkin lymphoma. Eligible patients have measurable disease, at least one site suitable for radiation, and are candidates for CAR-T therapy. The approach aims to modulate the disease environment before CAR-T and assess practical aspects such as safety and logistics. Primary goals focus on feasibility, with secondary observations on preliminary safety and treatment response. This is conducted at the Abramson Cancer Center with collaboration from the NCI.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female subject aged ≥ 18 years.
* Pathologically confirmed B-cell lymphoma patients intended for standard of care CAR-T
* ECOG Performance Status ≤ 2.
* Subjects must be clinically eligible to receive standard of care anti-CD19 CAR-T
* Subjects must have at least one site of disease amenable to radiation, with the ability to deliver radiation to at least 50% of involved sites
* Subjects must have at least one site of measurable disease based on CT or FDG PET
* Subjects must not be anticipated to require additional therapy beyond bridging radiation listed in this protocol for control of their lymphoma
* For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause.

The following age-specific requirements apply:

Women \< 50 years of age: amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).

Women ≥ 50 years of age: amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or had radiation-induced menopause with last menses \>1 year ago; or had chemotherapy-induced menopause with last menses \>1 year ago; or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).

* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
* Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion Criteria:

* Unable to take oral vancomycin for any reason, including: Allergy or Inability to swallow drug
* Known history of vancomycin resistant enterococcus (VRE)
* Contraindications to radiation therapy, including scleroderma, systemic lupus erythematosus, Crohn disease, ulcerative colitis, or idiopathic pulmonary fibrosis
* History of radiation pneumonitis or other grade 4 radiation-related adverse event
* Prior or concurrent malignancy whose natural history or treatment which has the potential to interfere with the safety or efficacy assessment of the radiation therapy are eligible for this trial.
* Severe, uncontrolled, significant intercurrent or recent illness that would exclude them from being a candidate for standard-of-care CART therapy.
* Known uncontrolled HIV infection with a detectable viral load at the time of screening. Note: Patients on effective antiretroviral therapy or who will plan on going on antiretroviral therapy at the time of screening are eligible for this trial. HIV testing is not required for eligibility.
* Active infection that required the use of antibiotics within 4 weeks prior to registration
* Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures

Where it's running

• Abramson Cancer Center, University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Elise Chong, MD — Abramson Cancer Center, University of Pennsylvania
• Study coordinator: Rachel Lundberg, PA-C
• Email: rachel.lundberg@pennmedicine.upenn.edu
• Phone: 215-615-5858

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma

  This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.

  Recruiting at 41 sites Phase 3 Lyell Immunopharma, Inc. · Gilbert, Arizona and 43 other locations · NCT07188558

• Evaluating GF-CART01 for treating relapsed or refractory B-cell cancers

  This study is testing a new CAR T cell therapy called GF-CART01 to see if it can help adults with tough-to-treat B-cell cancers that haven't responded to other treatments.

  Recruiting Phase 1 GenomeFrontier Therapeutics TW Co., Ltd. · Taipei · NCT06703892

• Using BHB with CAR-T therapy for lymphoma treatment

  This study is testing if taking a supplement called BHB while getting CAR-T therapy for large B-cell lymphoma can be safe and help improve the treatment's effects on the body.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT06610344

• Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07788118

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• TC011 (CD19 CAR-T) for relapsed or refractory large B‑cell lymphoma

  This will test a CD19-targeted CAR-T therapy called TC011 in adults whose large B‑cell lymphoma has relapsed or not responded after prior treatments.

  Recruiting Phase 1/2 TICAROS Co., Ltd. · Seoul, Seoul · NCT07473167

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.